Optimizing platelet inhibition

European Heart Journal, Supplement

Volumn 10, Issue D, 2008, Pages

  Van Giezen, J J J ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

AZD6140; Cangrelor; Clopidogrel; P2Y12 antagonists; Platelets; Prasugrel

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; ACETYLSALICYLIC ACID; AR 67085; AR 69931MX; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 3A4; ORBOFIBAN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; LOADING DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 67649492154     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sun009     Document Type: Conference Paper

References (21)

1. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
2. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
3. Fox KAA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202-1208.
4. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharm Ther 2007;81:735-741.
5. 12 antagonists. Semin Thromb Hemost 2005;31:195-204.
6. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5:1545-1551.
7. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
8. 12 antagonist AZD6140 compared with the thienopyridine clopidogrel in both a rat and a dog model of combined thrombosis and haemostasis. Presented at: The XXIst International Society on Thrombosis and Haemostasis Congress, Geneva, Switzerland; 6-12 July 2007.
9. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
10. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, for the DISPERSE2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE2 trial. J Am Coll Cardiol 2007;50: 1844-1851.
11. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
12. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
13. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, the TRITON- TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2015-2021.
14. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173.
15. 12 receptors. Presented at: The American Heart Association 2006 Scientific Sessions, Chicago, IL; 12-15 Nov 2006.
16. 12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004;24:1810-1815.
17. 12 antagonist AZD6140 inhibits ADP-induced contractions in mouse aorta, in addition to established inhibitory effects on platelet aggregation. Presented at: The 8th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Chicago, IL; 19-21 April 2007.
18. 12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol 2003;23:357-362.
19. von Beckerath N, Taubert D, Pogatsa-Murray G, Wieczorek A, Schomig E, Schomig A, Kastrati A. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Hemost 2005;93:789-791.
20. Wessels P, Heyns AD, Pieters H, Lötter MG, Badenhorst PN. An improved method for the quantification of the in vivo kinetics of a representative population of 111In-labelled human platelets. Eur J Nucl Med 1985;10:522-527.
21. Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Ernest CS, Jansen M, Jakubowski JA, Naganuma H, Wiviott SD, Winters KJ. Superior inhibition of platelet aggregation following a loading dose of CS-747 (prasugrel, LY640315) versus clopidogrel: correlation with the pharmacokinetics of active metabolite generation. J Thromb Haemost 2005;3(Suppl. 1): abstract P0952.